A Study to Assess Luspatercept in Lower-risk Myelodysplastic Syndrome Participants

Local Institution - 0016, Leuven

Local Institution - 0008, Roeselare

Local Institution - 0032, New York

Local Institution - 0045, Turin

Local Institution - 0036, Pittsburgh

Local Institution - 0039, Granada

Local Institution - 0029, Rozzano (MI)

Local Institution - 0031, Wheeling

Local Institution - 0015, Pavia

Local Institution - 0038, Madrid

Local Institution - 0014, Novara

Local Institution - 0040, Hanover

Local Institution - 0027, Ourense

Local Institution - 0056, Wellington

Local Institution - 0055, St. Petersburg

Local Institution - 0028, Salamanca

Local Institution - 0044, Tour Cedex01

Local Institution - 0018, Valencia

Local Institution - 0063, Valencia

Local Institution - 0011, Detroit

Local Institution - 0026, Angers

Local Institution - 0024, Florence

Local Institution - 0003, Milwaukee

Local Institution - 0059, St Louis

Local Institution - 0053, Pierre-Bénite

Local Institution - 0046, Paris

Local Institution - 0062, Napoli

Local Institution - 0013, München

Local Institution - 0001, Poitiers

Local Institution - 0021, Reggio Calabria

Local Institution - 0051, Los Alamitos

Local Institution - 0033, New Haven

Local Institution - 0020, Kansas City

Local Institution - 0025, Paducah

Local Institution - 0058, Morristown

Local Institution - 0054, Eugene

Local Institution - 0043, Amarillo

Local Institution - 0022, Huntsville

Local Institution - 0023, Prague

Local Institution - 0004, Prague

Local Institution - 0041, Nice

Local Institution - 0007, Grenoble

Local Institution - 0009, Leipzig

Local Institution - 0050, Rome

Local Institution - 0049, Lódz

Local Institution - 0010, Warsaw

Local Institution - 0034, Katowice

Local Institution - 0035, Wałbrzych

Local Institution - 0047, San Juan

Local Institution - 0017, L'Hospitalet de Llobregat

Local Institution - 0005, Barcelona

Local Institution - 0052, Barcelona